These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 22825461)

  • 1. Pathological possibilities and pitfalls in detecting aggressive bladder cancer.
    Mitra AP; Jordà M; Cote RJ
    Curr Opin Urol; 2012 Sep; 22(5):397-404. PubMed ID: 22825461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors.
    Giannopoulos A; Manousakas T; Gounari A; Constantinides C; Choremi-Papadopoulou H; Dimopoulos C
    J Urol; 2001 Aug; 166(2):470-5. PubMed ID: 11458049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
    Kumar A; Kumar R; Gupta NP
    Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The clinical efficacy of Bladder Chek NMP22 in urothelial cancer].
    Yokoyama T; Sekigawa R; Hayashi T; Horita S; Kanamuro T; Nonami Y; Sawada T; Nishikawa T; Kobayashi M; Yamaguchi Y; Ishida H; Goya N; Nakazawa H; Toma H
    Rinsho Byori; 2004 Mar; 52(3):199-203. PubMed ID: 15137316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison.
    Hautmann S; Toma M; Lorenzo Gomez MF; Friedrich MG; Jaekel T; Michl U; Schroeder GL; Huland H; Juenemann KP; Lokeshwar VB
    Eur Urol; 2004 Oct; 46(4):466-71. PubMed ID: 15363562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
    Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
    J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective evaluation of the diagnostic and potential prognostic utility of urinary human telomerase reverse transcriptase mRNA in patients with bladder cancer.
    Bowles L; Bialkowska-Hobrzanska H; Bukala B; Nott L; Razvi H
    Can J Urol; 2004 Dec; 11(6):2438-44. PubMed ID: 15636669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer.
    Shariat SF; Marberger MJ; Lotan Y; Sanchez-Carbayo M; Zippe C; Lüdecke G; Boman H; Sawczuk I; Friedrich MG; Casella R; Mian C; Eissa S; Akaza H; Serretta V; Huland H; Hedelin H; Raina R; Miyanaga N; Sagalowsky AI; Roehrborn CG; Karakiewicz PI
    J Urol; 2006 Sep; 176(3):919-26; discussion 926. PubMed ID: 16890655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuclear matrix protein-22: a prospective evaluation in a population at risk for bladder cancer. Results from the UroScreen study.
    Huber S; Schwentner C; Taeger D; Pesch B; Nasterlack M; Leng G; Mayer T; Gawrych K; Bonberg N; Pelster M; Johnen G; Bontrup H; Wellhäusser H; Bierfreund HG; Wiens C; Bayer C; Eberle F; Scheuermann B; Kluckert M; Feil G; Brüning T; Stenzl A;
    BJU Int; 2012 Sep; 110(5):699-708. PubMed ID: 22313585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accuracy of the ImmunoCyt assay in the diagnosis of transitional cell carcinoma of the urinary bladder.
    Feil G; Zumbrägel A; Päulgen-Nelde HJ; Hennenlotter J; Maurer S; Krause S; Bichler KH; Stenzl A
    Anticancer Res; 2003; 23(2A):963-7. PubMed ID: 12820331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
    Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular alterations associated with bladder cancer initiation and progression.
    Cordon-Cardo C
    Scand J Urol Nephrol Suppl; 2008 Sep; (218):154-65. PubMed ID: 18815930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine.
    Halling KC; King W; Sokolova IA; Karnes RJ; Meyer RG; Powell EL; Sebo TJ; Cheville JC; Clayton AC; Krajnik KL; Ebert TA; Nelson RE; Burkhardt HM; Ramakumar S; Stewart CS; Pankratz VS; Lieber MM; Blute ML; Zincke H; Seelig SA; Jenkins RB; O'Kane DJ
    J Urol; 2002 May; 167(5):2001-6. PubMed ID: 11956427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study.
    Pfister C; Chautard D; Devonec M; Perrin P; Chopin D; Rischmann P; Bouchot O; Beurton D; Coulange C; Rambeaud JJ
    J Urol; 2003 Mar; 169(3):921-4. PubMed ID: 12576813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [ImmunoCyt--a new urine test in diagnosis of bladder cancer].
    Feil G; Bichler KH; Päulgen-Nelde HJ; Hennenlotter J; Zumbrägel A; Stenzl A
    Urologe A; 2003 Apr; 42(4):531-7. PubMed ID: 12715125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence.
    Boman H; Hedelin H; Holmäng S
    J Urol; 2002 Jan; 167(1):80-3. PubMed ID: 11743280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology.
    Shariat SF; Casella R; Wians FH; Ashfaq R; Balko J; Sulser T; Gasser TC; Sagalowsky AI
    Eur Urol; 2004 Mar; 45(3):304-13; author reply 313. PubMed ID: 15036675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NMP22: a sensitive, cost-effective test in patients at risk for bladder cancer.
    Zippe C; Pandrangi L; Potts JM; Kursh E; Novick A; Agarwal A
    Anticancer Res; 1999; 19(4A):2621-3. PubMed ID: 10470205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Expression and clinical significance of nuclear matrix protein 22 and cytokeratin 18 in transitional cell carcinoma of the bladder].
    Song JW; DU LL; Zhao XW; Jing JX; Han CZ; Cui Y; Liu JW; Hao HL; Wang ZG; Mi ZG
    Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):274-7. PubMed ID: 19615282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High magnification cystoscopy in the primary diagnosis of bladder tumors.
    Jichlinski P; Lovisa B
    Curr Opin Urol; 2011 Sep; 21(5):398-402. PubMed ID: 21730856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.